Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy

Carfilzomib is a second-generation proteasome inhibitor approved for the treatment of multiple myeloma (MM). It seems to determine cardiovascular toxicity, primarily arterial hypertension. No predictive factors for cardiovascular adverse events (CVAEs) are known in patients affected by multiple myel...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancers (Basel)
Egile Nagusiak: Bruno, Giulia, Bringhen, Sara, Maffei, Ilaria, Iannaccone, Andrea, Crea, Teresa, Ravera, Agnese, Astarita, Anna, Vallelonga, Fabrizio, Salvini, Marco, Gay, Francesca, Veglio, Franco, Milan, Alberto
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6562621/
https://ncbi.nlm.nih.gov/pubmed/31058856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11050622
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak